Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | F2 | P00734 | 1/20 | 0.78 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163779 | 0.89 | NOTUM (0.64) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL8485436 | 0.89 | KCNJ1 (0.66) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL311636 | 0.89 | MAPT (1.00) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL82595 | 0.89 | MAPT (0.69) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL11716535 | 0.87 | NOTUM (0.62) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL3962509 | 0.85 | NOTUM (0.95) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL28994295 | 0.85 | NOTUM (0.95) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL1663879 | 0.85 | KCNJ1 (1.00) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL16083829 | 0.85 | NOTUM (0.77) | NOTUMMAPTF2KCNJ1ALDH1A1 | |
| SCHEMBL18472557 | 0.83 | KCNJ1 (0.70) | NOTUMMAPTF2KCNJ1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508488-A1 | USE OF A COPPER(II) AZIDE COMPLEX AS A PRIMARY EXPLOSIVE | EMTO GmbH (DE) | 2019-07-10 | — | — | EP | disclosed |
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012129452-A2 | PROPYNOIC ACID CARBAMOYL METHYL-ALMIDES AND PHARMACEUTICAL COMPOSITIONS AND METHODS BASED THEREON | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | RELA, NFE2, NCOA1 | NOTUM 1022/4885MAPT 1137/4885F2 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.